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use of ivabradine leads to a total cost saving of €4826 per patient
over 5 years. The use of ivabradine also leads to a higher effec-
tiveness, as it reduces the average number of revascularisation
procedures from 1.100 to 0.143, including the initial revasculari-
sation procedures for the standard care arm of the model. The
number of revascularisations during the 5-year period is about
similar, when excluding the initial revascularisation procedure
(0.100 to 0.143). Sensitivity analyses show that ivabradine
remains cost saving over the complete range of the input vari-
ables. CONCLUSIONS: Ivabradine is a cost-effective treatment
and, in fact, a dominant treatment: Ivabradine yields to a higher
effectiveness as standard treatment with respect to number of
revascularisations, but leads to substantial overall cost savings.
PODIUM SESSION II: ECONOMIC EVALUATIONS II
EE5
COST-EFFECTIVENESS OF ATORVASTATIN INTYPE 2
DIABETES PATIENTS:A PHARMACO-ECONOMIC ANALYSIS
OFTHE COLLABORATIVE ATORVASTATIN DIABETES STUDY
(CARDS) INTHE BELGIAN POPULATION
Marbaix S1,Vandenberghe H1,Van Gaal L2
1Pﬁzer WPO Belgium, Brussels, Belgium, 2Antwerp University Hospital,
Edegem, Belgium
OBJECTIVES: To estimate the cost-effectiveness of atorvastatin
10 mg compared with no treatment for the primary prevention of
cardiovascular (CV) events in Type 2 diabetes patients with no CV
history. METHODS: A Markov model with 1-year cycles was
developed to simulate theCV event and death risk according to the
therapeutic approach initiated. The transition probabilities for
CV event in the ‘no statin treatment’ group were derived from the
risk-equations reported from the large UK Prospective Diabetes
Study (UKPDS). The hazard ratio (HR) from the CARDS clinical
trial (0.63; 95% conﬁdence interval [CI], 0.48, 0.83; P = 0.001)
was used to adjust these CV event probabilities in the atorvastatin
10 mg treatment group. Characteristics of Type 2 diabetes
patients with no CV history were derived from the Belgian Opti-
mize Cardiovascular Prevention in Diabetes (OCAPI) survey. The
public health care payers’ perspective was taken into account for
costing. The direct medical costs of CV events were based on the
Public Health Authorities’ hospital database for acute care costs
and on literature for follow up costs. Drug cost did consider the
impact of generic entry on the reimbursement system. Costs were
valued at year 2008; costs and outcomes were respectively dis-
counted at 3 and 1.5%. RESULTS: Based on a 5-year time
horizon, atorvastatin was demonstrated to be cost-effective with
an incremental cost/QALYof €23,426.Over a lifetime horizon (25
years), atorvastatin was a cost-neutral therapeutic approach (€9/
QALY). At a threshold of €30,000/QALY, atorvastatin had a
99.3% probability to be cost-effective. Furthermore, for higher
risk diabetic patients managed in specialist hospital diabetes
centres, atorvastatin was cost-saving. CONCLUSIONS: Com-
pared to no treatment, the use of atorvastatin 10 mg as a primary
prevention strategy in Type 2 diabetes patients not only appears to
be cost-neutral over a lifetime, but improves CV outcomes.
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OBJECTIVES: Following broadening of the EMEA license for
advanced follicular lymphoma (FL) which now allows ﬁrst line
treatment with rituximab added to chemotherapy without
restriction to the regimen, we evaluated the cost-effectiveness of
rituximab added to commonly used chemotherapy regimens
from the perspective of the UK national health care system.
METHODS: A Markov model was developed using published
results from 4 phase III randomized-controlled clinical trials
evaluating progression-free survival (PFS) and overall survival
(OS) in patients with advanced FL. These trials compared the
addition of rituximab to chemotherapy regimens of either MCP,
CVP, CHOP or CHVP versus chemotherapy alone. Rates of
disease progression were derived from the PFS Kaplan-Meier
curves using parametric curve ﬁtting, mortality rates were
obtained from the Scotland-Newcastle Lymphoma Group data-
base and UK age-speciﬁc mortality tables. FL patient utilities
elicited using the EQ-5D were applied to PFS and progressed
health states. The duration of the treatment effect of rituximab
was applied for the period of follow-up speciﬁed in each of the
clinical trial publications. Medication, supportive care costs and
quality-adjusted life years (QALYs) were estimated over a life-
time time horizon (25 years) and discounted at 3.5% per annum.
Univariate and probabilistic sensitivity analysis was performed to
evaluate uncertainty. RESULTS: The addition of rituximab to
chemotherapy increased QALYs by 1.223, 1.034, 0.858 and
0.471 years for MCP, CVP, CHOP and CHVP, respectively, com-
pared to chemotherapy alone. The incremental cost per QALY
gained was £5620, £6455, £7970 and £8422, for MCP, CHOP,
CVP and CHVP, respectively, all below commonly used thresh-
olds in the UK. Sensitivity analyses indicated these results were
robust, and most sensitive to the duration of treatment effect.
CONCLUSIONS: For all chemotherapy regimens evaluated, the
model demonstrated the addition of rituximab increased quality-
adjusted life expectancy and is a highly cost-effective treatment
option for patients with advanced FL.
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OBJECTIVES: The impact of cervical cancer prevention,
through 12-year-old female vaccination with CervarixTM (Glaxo-
SmithKline), has been published for many countries at the
national level. However, to our knowledge no attempt has been
made to address the impact at a regional level. Since the Italian
health reforms of the early 1990s, introducing “managerialism”,
decentralization and quasi-market mechanisms; regional authori-
ties have consequently been experimenting with different orga-
nizational and funding models to achieve an acceptable
combination of equity, efﬁciency, freedom of choice and cost-
containment. METHODS: A Markov model, previously des-
cribed and successfully adapted to the national scenario (La
Torre, 2007), has been used to explore the impact of prophylactic
cervical cancer vaccination with CervarixTM at a regional level in
Italy. Resource use was based on a standard therapeutic path
applied to all regions. However we quantiﬁed the impact of the
so-called “decentralization progress” by collecting regional data
on: Pap-test coverage, tariffs for treatments and cost of the vac-
cination course. The analyses were combined with regional
budget impact analyses, considering the demography and the
effective tender price for each region. RESULTS: Our analyses
demonstrated the heterogeneity present at regional level in Italy
(e.g. regular screening, ranges from 36% to 84%; cost of cervical
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